

GREENWAY MEDICAL TECHNOLOGIES INC
 Form 3
 February 01, 2012

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>1. Name and Address of Reporting Person *</p> <p>Â INVESTOR AB</p> <p>(Last) (First) (Middle)</p> <p>C/O INVESTOR GROWTH CAPITAL,Â ONE ROCKEFELLER PLAZA, SUITE 2801</p> <p>(Street)</p> <p>NEW YORK,Â NYÂ 10020</p> <p>(City) (State) (Zip)</p> | <p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>02/01/2012</p> | <p>3. Issuer Name and Ticker or Trading Symbol</p> <p>GREENWAY MEDICAL TECHNOLOGIES INC [GWAY]</p> <p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)</p> | <p>5. If Amendment, Date Original Filed(Month/Day/Year)</p> <p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person</p> |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------|
| Common Stock | 1,235,295 | I | By Investor Growth Capital Limited <u>(1)</u> <u>(2)</u> |
| Common Stock | 529,411 | I | By Investor Group, L.P. <u>(1)</u> <u>(2)</u> |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: GREENWAY MEDICAL TECHNOLOGIES INC - Form 3

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|-----------------------------------------------|----------------------------------------------------------------|--------------------|--------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| Series A Convertible Preferred Stock | Â (3) | Â (3) | Common Stock | 2,210,526 (3) | \$ (3) | I | By Investor Growth Capital Limited (1) (2) |
| Series A Convertible Preferred Stock | Â (3) | Â (3) | Common Stock | 947,368 (3) | \$ (3) | I | By Investor Group, L.P. (1) (2) |
| Series B Convertible Preferred Stock | Â (4) | Â (4) | Common Stock | 768,637 (4) | \$ (4) | I | By Investor Growth Capital Limited (1) (2) |
| Series B Convertible Preferred Stock | Â (4) | Â (4) | Common Stock | 329,416 (4) | \$ (4) | I | By Investor Group, L.P. (1) (2) |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|-------------------------------------------------------------------------------------------------------|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| INVESTOR AB C/O INVESTOR GROWTH CAPITAL ONE ROCKEFELLER PLAZA, SUITE 2801 NEW YORK, NY 10020 | Â | Â X | Â | Â |

Signatures

/s/ Stephen Campe
01/31/2012
**Signature of Reporting Person Date

/s/ Michael Oporto
01/31/2012
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Investor AB, a publicly held Swedish company (the "Reporting Person"), through one or more entities, (i) wholly owns Investor Growth Capital Limited ("Investor Capital"), a Guernsey company, and (ii) is the ultimate general partner of Investor Group, L.P. ("Investor Group"), a Guernsey limited partnership. As a result of the foregoing, the Reporting Person possesses the sole power to vote and the sole power to direct the disposition of the shares of Greenway Medical Technologies, Inc. (the "Company") held by each of Investor Capital and Investor Group.

(2)

Edgar Filing: GREENWAY MEDICAL TECHNOLOGIES INC - Form 3

The Reporting Person's interest in all of the Company's securities is limited to the extent of its pecuniary interest in such securities, if any, and neither the filing of this statement nor any of its contents shall be deemed to constitute an admission by the Reporting Person or any other person/entity that he or it was or is the beneficial owner of any of the Company's securities for purposes of Section 16 of the Securities and Exchange Act of 1934 (the "Act"), or for any other purpose.

- (3) Each share of Series A Convertible Preferred Stock will automatically convert into 1.263 shares of common stock in connection with the completion of the Company's initial public offering and has no expiration date.
- (4) Each share of Series B Convertible Preferred Stock will automatically convert into one share of common stock in connection with the completion of the Company's initial public offering and has no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.